Re: RVX-297 vs RVX-208 for autoimmune indications
in response to
by
posted on
Jan 09, 2019 09:35AM
And just to make everyone's head spin a little more this AM, there is BD1 vs. BD2 selectivity, and then there is BRD specificity (i.e. BRD2, BRD4, etc). Rndtbl posted over on IV this AM about two compounds ZL-0420 and ZL-0454 that are not really selective for BD1 vs. BD2 but seem to be 30-60 fold more selective for the BDs of BRD4 over the BDs of BRD2. Rndtbl also linked to an article from Univ of Texas Health Center about efforts to develop novel formulation of BET inhibs to treat airway inflammation and COPD. Thanks Rndtbl! Very interesting.
BDAZ